85 related articles for article (PubMed ID: 17847034)
1. Systemic administration of a peptide that impairs the protein kinase (CK2) phosphorylation reduces solid tumor growth in mice.
Perera Y; Farina HG; Hernández I; Mendoza O; Serrano JM; Reyes O; Gómez DE; Gómez RE; Acevedo BE; Alonso DF; Perea SE
Int J Cancer; 2008 Jan; 122(1):57-62. PubMed ID: 17847034
[TBL] [Abstract][Full Text] [Related]
2. Antitumor effect of a novel proapoptotic peptide that impairs the phosphorylation by the protein kinase 2 (casein kinase 2).
Perea SE; Reyes O; Puchades Y; Mendoza O; Vispo NS; Torrens I; Santos A; Silva R; Acevedo B; López E; Falcón V; Alonso DF
Cancer Res; 2004 Oct; 64(19):7127-9. PubMed ID: 15466209
[TBL] [Abstract][Full Text] [Related]
3. CIGB-300, a novel proapoptotic peptide that impairs the CK2 phosphorylation and exhibits anticancer properties both in vitro and in vivo.
Perea SE; Reyes O; Baladron I; Perera Y; Farina H; Gil J; Rodriguez A; Bacardi D; Marcelo JL; Cosme K; Cruz M; Valenzuela C; López-Saura PA; Puchades Y; Serrano JM; Mendoza O; Castellanos L; Sanchez A; Betancourt L; Besada V; Silva R; López E; Falcón V; Hernández I; Solares M; Santana A; Díaz A; Ramos T; López C; Ariosa J; González LJ; Garay H; Gómez D; Gómez R; Alonso DF; Sigman H; Herrera L; Acevedo B
Mol Cell Biochem; 2008 Sep; 316(1-2):163-7. PubMed ID: 18575815
[TBL] [Abstract][Full Text] [Related]
4. Anticancer peptide CIGB-300 binds to nucleophosmin/B23, impairs its CK2-mediated phosphorylation, and leads to apoptosis through its nucleolar disassembly activity.
Perera Y; Farina HG; Gil J; Rodriguez A; Benavent F; Castellanos L; Gómez RE; Acevedo BE; Alonso DF; Perea SE
Mol Cancer Ther; 2009 May; 8(5):1189-96. PubMed ID: 19417160
[TBL] [Abstract][Full Text] [Related]
5. CIGB-300, an anti-CK2 peptide, inhibits angiogenesis, tumor cell invasion and metastasis in lung cancer models.
Benavent Acero F; Capobianco CS; Garona J; Cirigliano SM; Perera Y; Urtreger AJ; Perea SE; Alonso DF; Farina HG
Lung Cancer; 2017 May; 107():14-21. PubMed ID: 27319334
[TBL] [Abstract][Full Text] [Related]
6. Antitumor efficacy, pharmacokinetic and biodistribution studies of the anticancer peptide CIGB-552 in mouse models.
Vallespí MG; Pimentel G; Cabrales-Rico A; Garza J; Oliva B; Mendoza O; Gomez Y; Basaco T; Sánchez I; Calderón C; Rodriguez JC; Markelova MR; Fichtner I; Astrada S; Bollati-Fogolín M; Garay HE; Reyes O
J Pept Sci; 2014 Nov; 20(11):850-9. PubMed ID: 25044757
[TBL] [Abstract][Full Text] [Related]
7. CK2 mediates phosphorylation and ubiquitin-mediated degradation of the PML tumor suppressor.
Scaglioni PP; Yung TM; Choi S; Baldini C; Konstantinidou G; Pandolfi PP
Mol Cell Biochem; 2008 Sep; 316(1-2):149-54. PubMed ID: 18566754
[TBL] [Abstract][Full Text] [Related]
8. Influence of casein kinase II in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human rhabdomyosarcoma cells.
Izeradjene K; Douglas L; Delaney A; Houghton JA
Clin Cancer Res; 2004 Oct; 10(19):6650-60. PubMed ID: 15475455
[TBL] [Abstract][Full Text] [Related]
9. Preclinical efficacy of CIGB-300, an anti-CK2 peptide, on breast cancer metastasic colonization.
Gottardo MF; Capobianco CS; Sidabra JE; Garona J; Perera Y; Perea SE; Alonso DF; Farina HG
Sci Rep; 2020 Sep; 10(1):14689. PubMed ID: 32895446
[TBL] [Abstract][Full Text] [Related]
10. CIGB-300: A peptide-based drug that impairs the Protein Kinase CK2-mediated phosphorylation.
Perea SE; Baladrón I; Valenzuela C; Perera Y
Semin Oncol; 2018 Jan; 45(1-2):58-67. PubMed ID: 30318085
[TBL] [Abstract][Full Text] [Related]
11. Antitumor effect of TAT-oxygen-dependent degradation-caspase-3 fusion protein specifically stabilized and activated in hypoxic tumor cells.
Harada H; Hiraoka M; Kizaka-Kondoh S
Cancer Res; 2002 Apr; 62(7):2013-8. PubMed ID: 11929818
[TBL] [Abstract][Full Text] [Related]
12. MET tyrosine kinase inhibitor crizotinib (PF-02341066) shows differential antitumor effects in non-small cell lung cancer according to MET alterations.
Tanizaki J; Okamoto I; Okamoto K; Takezawa K; Kuwata K; Yamaguchi H; Nakagawa K
J Thorac Oncol; 2011 Oct; 6(10):1624-31. PubMed ID: 21716144
[TBL] [Abstract][Full Text] [Related]
13. Chimeric peptides as modulators of CK2-dependent signaling: Mechanism of action and off-target effects.
Zanin S; Sandre M; Cozza G; Ottaviani D; Marin O; Pinna LA; Ruzzene M
Biochim Biophys Acta; 2015 Oct; 1854(10 Pt B):1694-707. PubMed ID: 25936516
[TBL] [Abstract][Full Text] [Related]
14. [Effects of a protein kinase C inhibitor combined with cisplatin on non-small cell lung cancer].
Gao ZQ; Han BH; Sha HF; Shi ZY; Yang XH; Feng JX
Zhonghua Jie He He Hu Xi Za Zhi; 2010 Apr; 33(4):284-8. PubMed ID: 20646461
[TBL] [Abstract][Full Text] [Related]
15. Enhanced antitumor effects of the BRBP1 compound peptide BRBP1-TAT-KLA on human brain metastatic breast cancer.
Fu B; Long W; Zhang Y; Zhang A; Miao F; Shen Y; Pan N; Gan G; Nie F; He Y; Zhang J; Teng G
Sci Rep; 2015 Jan; 5():8029. PubMed ID: 25619721
[TBL] [Abstract][Full Text] [Related]
16. [shRNA-mediated insulin-like growth factor I receptor gene silencing inhibits cell proliferation, induces cell apoptosis, and suppresses tumor growth in non-small cell lung cancer: in vitro and in vivo experiments].
Dong AQ; Kong MJ; Ma ZY; Qian JF; Fan JQ; Xu XH
Zhonghua Yi Xue Za Zhi; 2007 Jun; 87(21):1506-9. PubMed ID: 17785094
[TBL] [Abstract][Full Text] [Related]
17. Protein kinase CK2 catalyzes tyrosine phosphorylation in mammalian cells.
Vilk G; Weber JE; Turowec JP; Duncan JS; Wu C; Derksen DR; Zien P; Sarno S; Donella-Deana A; Lajoie G; Pinna LA; Li SS; Litchfield DW
Cell Signal; 2008 Nov; 20(11):1942-51. PubMed ID: 18662771
[TBL] [Abstract][Full Text] [Related]
18. Tat-SmacN7 induces radiosensitization in cancer cells through the activation of caspases and induction of apoptosis.
Chen F; Xu C; Du L; Wang Y; Cao J; Fu Y; Guo Y; Liu Q; Fan F
Int J Oncol; 2013 Mar; 42(3):985-92. PubMed ID: 23338568
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of platelet-derived growth factor receptor α by MEDI-575 reduces tumor growth and stromal fibroblast content in a model of non-small cell lung cancer.
Laing N; McDermott B; Wen S; Yang D; Lawson D; Collins M; Reimer C; Hall PA; Andersén H; Snaith M; Wang X; Bedian V; Cao ZA; Blakey D
Mol Pharmacol; 2013 Jun; 83(6):1247-56. PubMed ID: 23558446
[TBL] [Abstract][Full Text] [Related]
20. Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition.
Thomson S; Buck E; Petti F; Griffin G; Brown E; Ramnarine N; Iwata KK; Gibson N; Haley JD
Cancer Res; 2005 Oct; 65(20):9455-62. PubMed ID: 16230409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
